• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

Cancer Management Platform Receives FDA Clearance


Avenda Health's iQuest combines existing patient-specific diagnostic information and deep-learning algorithms.

AI healthcare company Avenda Health announced its cancer management platform, iQuestTM, has received 510(k) clearance by the FDA.

iQuest combines existing patient-specific diagnostic information and deep-learning algorithms to create a tailored map of where cancer is within the prostate to enable a physician to make decisions that consider the cancer extent rather than treating the whole organ. This information supports physicians and patients with treatment selection, planning, guidance, and follow-up.

According to the company, its process advances the standard of care in prostate cancer as current MRI technology cannot identify the full extent of the tumor and cancer growth within the prostate. This results in nearly 50% of patients losing their sexual or urinary function.

iQuest can be applied to multiple treatment options to guide a doctor's intervention plan, including FocalPoint—Avenda Health's soft tissue laser ablation device—and other focal treatments, active surveillance, and decision-making for whole gland treatments including radical prostatectomy and radiation therapy.

Read more about iQuest.

© 2024 MJH Life Sciences

All rights reserved.